Navigation Links
SteriFx Inc. Provides 'Solutions' to Combat Campylobacter
Date:3/25/2009

Antimicrobial Developer Adds New Measurement Tool to Assist Processing Plants.

SHREVEPORT, La., March 25 /PRNewswire/ -- Since 2003, SteriFx Inc. and its FreshFx antimicrobial solutions have proven to be effective on the poultry processing line against Campylobacter jejuni (Campy), as well as Salmonella, E. coli, and Listeria. Now SteriFx can provide plant management another tool to help control Campylobacter by pre-screening birds for their current load of Campy at various points throughout processing.

"SteriFx now has the ability to measure levels of Campylobacter, and we can help processors get current levels in order to be better prepared for any new testing requirements," said John R. Dankert, Ph.D., CEO of SteriFx. "We have been successful in this regard for Salmonella, E. coli, and aerobic counts, and now can offer Campylobacter analysis."

Campylobacter species have been recognized as one of the leading causes of food illness in the United States. According to the Centers for Disease Control and Prevention (CDC), Campy is diagnosed in 13 cases each year for every 100,000 persons - although many more cases go undetected. It is estimated to impact over 2.5 million people annually, with 100 to 200 deaths per year. A substantial portion of the illnesses and deaths are associated with meat and poultry.

To combat Campy in poultry processing plants, SteriFx personnel can provide Microbiological Testing Services, from collection of samples to data analysis. By using FreshFx antimicrobial solutions as part of a company's Hazard Analysis and Critical Control Points (HACCP) efforts, it can control Campy and other pathogens - greatly reducing the risk of product recalls and helping to maintain consumer health.

FreshFx antimicrobial solutions are clear, odorless, digestible aqueous liquids that are non-toxic despite the low pH. They are easy-to-use
'/>"/>

SOURCE SteriFx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Dr. Kenneth L. Byrd Joins SteriFx Inc.
2. Study provides hope that some transplant patients could live free of antirejection drugs
3. Study provides hope that some transplant patients could live free of anti-rejection drugs
4. USAID Provides Additional Wildfire Assistance to Greece
5. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
6. New knock-out gene model provides molecular clues to breast cancer
7. PreMD Provides Update on 510(k) Application for PREVU(x) POC
8. SIV infection of natural hosts provides new insights into HIV disease complexity
9. Microarray provides 3 genomic guides to breast cancer treatment decisions
10. Access Innovations Provides Support Services for Agis Network
11. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Hard to Treat Diseases (HTDS.PK) Business Summary Update 2Health News:Hard to Treat Diseases (HTDS.PK) Business Summary Update 3Health News:Hard to Treat Diseases (HTDS.PK) Business Summary Update 4Health News:Quantros(TM) Unveils Clinical Cafe, Social Networking Website for Healthcare Professionals Focused on Safety, Quality and Compliance 2Health News:Quantros(TM) Unveils Clinical Cafe, Social Networking Website for Healthcare Professionals Focused on Safety, Quality and Compliance 3Health News:Delinquent boys at increased risk of premature death and disability by middle age 2Health News:Delinquent boys at increased risk of premature death and disability by middle age 3Health News:BridgeGate International Announces New Integration and Interoperability Training Program 2Health News:BridgeGate International Announces New Integration and Interoperability Training Program 3Health News:BridgeGate International Announces New Integration and Interoperability Training Program 4Health News:Sex Talk Taking Place After the Fact 2Health News:Sex Talk Taking Place After the Fact 3
Breaking Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 2Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program 3Mirixa Corporation Announces Key New Hires 12958 1Mirixa Corporation Announces Key New Hires 12958 2Landmark project to map genomics of complex ant systems 9188 1Landmark project to map genomics of complex ant systems 9188 2European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 1European Health Care Institutions Forced to Select Lower Priced Interventional Cardiology Devices 51202 2